2014 PERSIST-1 Trial is now recruiting for Phase 3

June 18, 2014

Clinical Trial Alert

A randomized, controlled Phase 3 study of oral Pacritinib vs. best available therapy for patients with myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis is anticipated to be closing soon. If you, or someone you know, is interested in participating in this study, click here for more information via ClinicalTrials.gov and/or contact Gordon Thomson at gthomson@ockham.com and indicate PERSIST-1 in the subject line, or call +44 (0) 131-440-6441.

As with any medical decision, you should discuss participation in this or any clinical trial with your physician and family. There are pros and cons to any medical study.

Take the steps you need to help change your prognosis.



Get free, timely information on living with an MPN.